B体育直播·(B-sports)官方网站

A Pioneer In Immune Cell and Gene-based Therapies

Learn More*
About our anti-cancer portfolio technology

Our immunotherapy portfolio* is designed to recognize and kill highly-expressed multiple tumor targets. With more than 20 years of R&D in different immune therapies to treat blood cancer and solid tumors, GIMI has a broad and extensive portfolio of target approaches for CAR-T therapy, Engineered Immune Effector (EIE) therapy, and Dendritic Cell (DC) vaccines.

In clinical studies, our immune therapy products have shown high safety and efficacy, contributing to durable anti-tumor responses.

Our immunotherapy portfolio has been applied to over 1000 patients in different clinical trials through collaborations with different hospitals targeting both hematological malignancies and solid tumors.

In a 2018 article published in Nature Reviews Drug Discovery by Dr. Jun Tang and colleagues, the global landscape of immuno-oncology research was summarized. The study highlighted 655 institutions worldwide that were engaged in related research, with four of the top 15 institutions being research organizations—three from China. The highest-ranked institution listed is ShenZhen Geno-immune Medical Institute.

According to 2022 statistics from BioClub, the United States leads in immune cell therapy development with 1,336 active projects, followed by China (498 projects), South Korea (141), the UK (138), and Japan (136). Among corporate and institutional rankings, the ShenZhen Geno-immune Medical Institute topped the list domestically.

Learn More

Several clinical studies are ongoing and planned with different portfolio immune strategies.

Developing innovative gene and immunological therapies for blood and solid tumor cancers, autoimmune and genetic diseases, and infectious diseases, GIMI has positioned itself in a broad frontline against genetic and autoimmune diseases, infections and cancer.

Based on positive results of the immunological products in various blood and solid tumor cancers, we are now pursuing both lymphoid and myeloid leukemia as our lead indications with the goal of broadening patient treatment options. We are currently enrolling patients in the safety lead-in portion of our multicenter randomized Phase 1/2 studies. See clinical trials**.

Blood Cancer Research
- Case 12: South America B-Acute Lymphoblastic Leukemia (B-ALL) boy came to China for 4SCART therapy…
  Cancer History: First diagnosis of cancer: 12/2018 Primary disease: B-ALL
- Cases 10: The first Japanese CART patients receiving 4SCART therapy
  4 cases of pediatric acute lymphoblastic leukemia with central nervous system
- Case 9: The patient with mucosa-associated lymphoid tissue lymphoma for many years achieved PR
  A 75 year-old woman sufferred with mucosa-associated lymphoid tissue lymphoma (MALT) for many years
- Case 8: The patient of high burden refractory Burkitt lymphoma in CR
  A 34 year-old man with high burden refractory Burkitt’s lymphoma
Solid Organ Cancer Research
- Case 13: Long term remission in a 2-year-old patient with refractory/recurrent rhabdomyosarcoma
  First diagnosis of cancer: 09/2013 Rhabdomyosarcoma (RMS) IIIa, cT2aN0M0
- Case 11: The world first successful lentiviral gene therapy treating CGD
  A 2-month-old boy with X-CGD
- Case5： PR in a patient suffering from glioblastoma with relapse
  A 43 year-old male suffering from glioblastoma with relapse
- Case 1: achieving 9 years of CR in a cervical cancer patient
  A 34 year-old woman with cervical cancer and right pelvic pain

Clinical TrialsLEARN MORE

Our immune therapies portfolio are evaluated in several clinical studies across blood derived malignancies and solid tumors.

GIMI provides innovative, personalized medical referral service to patients from around the world. We have an extensive collaboration hospitals in China dedicated to providing advanced and compassionate medical service.

We welcome all cases, including the rarest and the most challenging patients. Our medical teams endeavor to achieve the best possible health benefits and outcomes. From the initial inquiry through the long-term follow-up care, we are here for you.